Celldex’s Barzolvolimab Shows Long-term Efficacy in Phase 2 CSU Study
Celldex’s barzolvolimab demonstrated profound, sustained complete response and improved quality of life at 76 weeks in patients with chronic spontaneous urticaria (CSU), seven months after the completion of dosing